News

October 12, 2017

Assessing the Economics of Single-Source vs. Multi-Vendor Manufacturing

This report examines the impact on development costs and net returns for drug developers if clinical development cycle times are reduced, which has implications for development efficiency, innovation incentives, and earlier access by patients to new therapies. The analysis is conducted in the context of estimated differences in development times between single-source and multi-source outsourced contract manufacturing. The full study has been submitted for peer-reviewed publication. 

View the Tufts CSDD White Paper here

ABOUT RESEARCH COURSES & FORUMS LIBRARY & BIBLIOGRAPHY REPORTS SPONSORED RESEARCH NEWS